D425 Med Xenograft Model Service for Medulloblastoma

The D425 Med xenograft model is a well-established, highly aggressive Group 3 medulloblastoma platform that enables robust preclinical evaluation of novel therapeutics targeting MYC-driven pediatric brain tumors. Alfa Cytology leverages this clinically relevant model to deliver precise, reproducible xenograft studies, supporting your drug development pipeline with rigorous in vivo pharmacology and comprehensive endpoint analysis.

Overview of D425 Med Xenograft Model for Medulloblastoma

Medulloblastoma is the most common malignant pediatric brain tumor, with the highest incidence occurring in children between 6 and 8 years of age. The D425 Med cell line was established from a primary tumor biopsy of a 6-year-old male patient and is classified as Group 3 medulloblastoma, characterized by MYC amplification and mutant p53. This molecular profile is associated with the most aggressive disease subtype, marked by high metastatic potential and poor clinical prognosis. D425 Med cells exhibit a neuronal phenotype, expressing neurofilament proteins and synaptophysin while remaining negative for glial fibrillary acidic protein (GFAP), consistent with their neuroectodermal origin. The cell line grows as suspended or lightly adherent clumps in culture and has been extensively validated as a transplantable xenograft model in immunodeficient mice.

As a preclinical model, the D425 Med xenograft faithfully recapitulates key features of human Group 3 medulloblastoma, including rapid tumor growth, leptomeningeal dissemination, and sensitivity to standard-of-care chemotherapeutics such as vincristine and temozolomide. Orthotopic implantation into the cerebellum of NOD-SCID or NSG mice produces tumors that closely mimic the anatomical location and invasive behavior of the human disease. The model has been widely utilized to evaluate targeted therapies, including BET-bromodomain inhibitors, Rho-associated kinase (ROCK) inhibitors, and carbonic anhydrase inhibitors, providing critical insights into drug efficacy, pharmacokinetics, and mechanism of action in a physiologically relevant brain tumor microenvironment.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting MYC-driven Group 3 medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression and leptomeningeal dissemination, and how treatments intersect with MYC amplification and mutant p53 signaling.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. MAGMAS inhibition induces medulloblastoma cell death. Representative images show DAOY (A and B) and D425 (C and D) cells treated with vehicle control (A and C) or BT9 (B and D). (Motahari, Zahra, et al., 2024)

Cell Line Information: D425 Med

The D425 Med cell line is one of the most extensively characterized and highly cited models for Group 3 medulloblastoma research. Derived from a primary posterior fossa tumor, this line has been authenticated by short tandem repeat (STR) profiling and is negative for Mycoplasma contamination. Its neuronal phenotype and MYC-driven molecular profile make it unique among available medulloblastoma cell lines and essential for preclinical research targeting the most aggressive pediatric brain tumor subtype.

Our Services

Alfa Cytology provides comprehensive D425 Med xenograft model services tailored to your preclinical research objectives. From study design and ethical protocol approval to tumor implantation, in-life monitoring, and terminal endpoint analysis, our experienced team ensures rigorous data quality and regulatory compliance. We offer flexible dosing schedules, multi-parameter readouts-including tumor volume measurements, bioluminescence imaging, survival analysis, histopathology, and biomarker quantification-to accelerate your therapeutic development timeline.

Workflow of D425 Med Xenograft Model Construction

The construction of a D425 Med xenograft model follows a standardized, GLP-compliant workflow that ensures reproducible tumor engraftment and reliable pharmacological readouts. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Culture and Quality Control: D425 Med cells are expanded under defined culture conditions (DMEM/F12, 10% FBS, 1% antibiotics) and authenticated by STR profiling prior to implantation. Mycoplasma testing is performed to confirm sterility. Cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium at a concentration of 1x10^6 to 5x10^6 cells per injection site.
2. Animal Preparation and Ethical Approval: Immunodeficient mice (NOD-SCID or NSG, 6-10 weeks old) are acclimatized under pathogen-free conditions. All procedures are conducted under IACUC-approved protocols with humane endpoints predefined. Mice are randomized into treatment and control cohorts based on body weight.
3. Tumor Cell Implantation: For orthotopic models, mice are anesthetized and positioned in a stereotactic frame. D425 cells are injected into the cerebellar vermis using coordinates approximately 2 mm posterior to lambda, 1 mm lateral, and 1.5-2 mm deep, at a volume of 5-10 uL. For subcutaneous models, cells are injected into the flank in a 1:1 mixture with Matrigel. Luciferase-labeled cells may be used to enable non-invasive bioluminescence monitoring.
4. In-Life Monitoring and Tumor Tracking: Mice are monitored daily for body weight, neurological signs, and overall health status. Tumor growth is quantified by caliper measurements (subcutaneous) or bioluminescence imaging (orthotopic) at defined intervals (e.g., weekly). Humane endpoints are applied based on tumor burden, weight loss >20%, or neurological deterioration.
5. Treatment Administration and Dosing: Test compounds are administered via oral gavage, intraperitoneal injection, or intravenous tail-vein injection according to the study design. Dosing regimens are optimized based on compound solubility, half-life, and target engagement. Vehicle controls receive matched formulation without active compound.
6. Endpoint Analysis and Sample Collection: At study termination, mice are euthanized and tumors are excised, weighed, and photographed. Tissues are processed for histopathology (H&E, IHC), immunofluorescence, RNA/DNA extraction, flow cytometry, and pharmacokinetic analysis. Survival data are analyzed by Kaplan-Meier methodology.

Figure 2: Schematic workflow illustrating the derivation and construction of the D425 Med Xenograft Model at Alfa Cytology.

Case Study-D425 Med Xenograft Model Development

Alfa Cytology has successfully established and validated the D425 Med orthotopic xenograft model for multiple preclinical drug development programs. In a representative study, luciferase-expressing D425 cells were stereotactically implanted into the cerebella of NSG mice, with robust tumor engraftment confirmed by serial bioluminescence imaging within 7-14 days post-implantation. Tumor-bearing mice were randomized to receive either vehicle control or investigational therapeutic agents, with survival and tumor burden monitored longitudinally. Comprehensive endpoint analysis included tumor volume quantification, histopathological characterization, and molecular biomarker profiling. Detailed efficacy data, survival curves, and pharmacodynamic readouts are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology is a specialized preclinical CRO dedicated to advancing oncology drug discovery through robust, clinically relevant tumor models. Our D425 Med xenograft service combines scientific expertise with operational excellence to deliver actionable data for your development pipeline.

• Verified Cell Line Integrity: Authenticated cell lines with verified STR profiles and routine Mycoplasma screening ensure model integrity and reproducibility across studies.
• High Take Rates and Consistency: Standardized orthotopic and subcutaneous implantation protocols, supported by stereotactic surgical expertise, achieve high engraftment rates with minimal procedural variability.
• Integrated Imaging Capabilities: Integrated in vivo imaging capabilities (bioluminescence, MRI) enable real-time, non-invasive tumor monitoring and quantitative pharmacodynamic assessments.
• Comprehensive Analytical Support: Comprehensive endpoint analysis including histopathology, immunohistochemistry, flow cytometry, and molecular profiling provides mechanistic insights beyond simple efficacy readouts.
• Tailored Study Designs: Flexible study designs accommodate single-agent, combination, dose-escalation, and pharmacokinetic/pharmacodynamic (PK/PD) evaluations with rapid turnaround times.
• Standardized Protocols: All studies are conducted under IACUC-approved protocols with rigorous adherence to animal welfare guidelines, ensuring ethical and regulatory compliance.

Contact Us

Ready to advance your medulloblastoma therapeutic program? Contact us today to discuss your specific study requirements, receive a customized proposal, and learn how Alfa Cytology's D425 Med xenograft model can accelerate your preclinical development. Our scientific team is available to reach out to you with detailed protocols, feasibility assessments, and timeline estimates tailored to your research goals. Please reach out to us today via our inquiry form or email to learn more about our D425 Med Xenograft Model services.

For research use only. Not intended for any clinical use.